Clinical Trial Update: Safety and Efficacy of MCC-257 in the Treatment of Diabetic Polyneuropathy [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating MCC-257 for diabetic polyneuropathy reported safety and efficacy results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Polyneuropathy

Drugs mentioned

• MCC-257

Snippet

Sponsor: Tanabe Pharma Corporation | Conditions: Diabetic Polyneuropathy | Phase 2 | Status: COMPLETED